Similar articles

• Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: behavioral effects and induction of c-fos-like immunoreactivity.

  Johnson KB, Criswell HE, Jensen KF, Simson PE, Mueller RA, Breese GR. Johnson KB, et al. J Pharmacol Exp Ther. 1992 Aug;262(2):855-65. J Pharmacol Exp Ther. 1992. PMID: 1354257
• A68930: a potent agonist selective for the dopamine D1 receptor.

  DeNinno MP, Schoenleber R, MacKenzie R, Britton DR, Asin KE, Briggs C, Trugman JM, Ackerman M, Artman L, Bednarz L, et al. DeNinno MP, et al. Eur J Pharmacol. 1991 Jun 25;199(2):209-19. doi: 10.1016/0014-2999(91)90459-4. Eur J Pharmacol. 1991. PMID: 1683288
• A68930: a potent and specific agonist for the D-1 dopamine receptor.

  Kebabian JW, Briggs C, Britton DR, Asin K, DeNinno M, MacKenzie RG, McKelvy JF, Schoenleber R. Kebabian JW, et al. Am J Hypertens. 1990 Jun;3(6 Pt 2):40S-42S. doi: 10.1093/ajh/3.6.40s. Am J Hypertens. 1990. PMID: 2143387 Review.
• Neurobiology of D1 dopamine receptors after neonatal-6-OHDA treatment: relevance to Lesch-Nyhan disease.

  Breese GR, Mueller RA, Napier TC, Duncan GE. Breese GR, et al. Adv Exp Med Biol. 1986;204:197-215. doi: 10.1007/978-1-4684-5191-7_13. Adv Exp Med Biol. 1986. PMID: 2947429 Review. No abstract available.
• Synthesis and dopaminergic activity of 3-substituted 1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyrans: characterization of an auxiliary binding region in the D1 receptor.

  DeNinno MP, Schoenleber R, Perner RJ, Lijewski L, Asin KE, Britton DR, MacKenzie R, Kebabian JW. DeNinno MP, et al. J Med Chem. 1991 Aug;34(8):2561-9. doi: 10.1021/jm00112a034. J Med Chem. 1991. PMID: 1652023